Sangamo: Phase 3 hemophilia A gene therapy succeeds; share authorization suit resolved

SANGAMO THERAPEUTICS, INC

Phase 3 AFFINE trial met primary endpoint: mean ABRtotal reduced from 4.73 (prophylaxis) to 1.24 post infusion (p=0.004).
84% of participants (42/50) achieved FVIII activity >5% at Month 15; 88% had no treated bleeds.
Safety: no FVIII inhibitors, no treatment-related malignancies; ALT elevations manageable with corticosteroids.
Delaware Court validated share increase vote standard; Sangamo dismissed Section 205 application.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.